Sales of Pfizer’s new vaccine for respiratory syncytial virus were lower in the third quarter than during the same period last year, but the company pointed to signs of growing market share as reason for confidence in the shot’s market potential.

辉瑞（Pfizer）新型呼吸道合胞病毒疫苗第三季度的销售额低于去年同期，但该公司指出，市场份额不断增长的迹象是对该疫苗市场潜力充满信心的原因。

Between July and September, Abrysvo brought Pfizer $356 million in sales globally, compared to last year’s total of $375 million, according to third quarter earnings Pfizer reported Tuesday. Revenue across the first nine months was higher, reaching $557 million versus the $375 million last year, because Abrysvo wasn’t approved in the U.S.

根据辉瑞周二公布的第三季度财报，7月至9月期间，Abrysvo为辉瑞带来了3.56亿美元的全球销售额，而去年的总销售额为3.75亿美元。前九个月的收入更高，达到5.57亿美元，而去年为3.75亿美元，因为Abrysvo未在美国获得批准。

for older adults until the end of May last year..

截至去年5月底的老年人。。

So far, Pfizer has trailed competitor GSK, which has been able to dominate the nascent RSV vaccine market with its shot Arexvy, despite it only winning approval weeks earlier.

迄今为止，辉瑞（Pfizer）落后于竞争对手葛兰素史克（GSK），尽管其在几周前才获得批准，但葛兰素史克（GSK）仍能凭借其疫苗Arexvy在新生的RSV疫苗市场占据主导地位。

However, Pfizer said Abrysvo’s market share has increased, exceeding 50% of shipped volume for the third quarter. Abrysvo’s slice of vaccinations in the retail setting has also climbed for “nine consecutive weeks through mid-October, currently reaching 43%,” Pfizer CEO Albert Bourla said in prepared remarks..

。辉瑞公司首席执行官阿尔伯特·博拉在准备好的讲话中表示，Abrysvo在零售环境中的疫苗接种比例也“连续九周攀升至10月中旬，目前已达到43%”。。

Both companies are working to expand the number of people eligible for vaccination. Last week, the Food and Drug Administration cleared Abrysvo for use in certain adults aged 18 years to 59 years old who are at higher risk of RSV-related disease. Previously it only had been available for adults 60 years or older, or for pregnant women..

两家公司都在努力扩大有资格接种疫苗的人数。上周，美国食品和药物管理局批准Abrysvo用于某些18岁至59岁的成年人，这些成年人患RSV相关疾病的风险较高。以前它只适用于60岁以上的成年人或孕妇。。

On a conference call Tuesday, Pfizer’s commercial chief Aamir Malik said the company is seeing “really good momentum” in maternal vaccination. Over the first four weeks of the season, Malik said, Pfizer shipped 56% more units of Abrysvo to obstetricians and gynecologists in health systems than during the same period last year..

在周二的一次电话会议上，辉瑞公司商业主管阿米尔·马利克（AamirMalik）表示，该公司在孕产妇疫苗接种方面取得了“非常好的势头”。马利克说，在本季度的前四周，辉瑞公司向卫生系统的妇产科医生运送的Abrysvo数量比去年同期多56%。。

However, uptake among older adults has been disrupted somewhat by recommendations provided this summer by the Centers for Disease Control and Prevention. The agency narrowed its guidance to urge vaccination most heavily in adults over 75 years old and in those aged 60 to 74 years who are at higher risk..

然而，疾病控制和预防中心今年夏天提供的建议在一定程度上打乱了老年人的摄取。该机构缩小了指导范围，敦促75岁以上的成年人和60至74岁的高危人群接种疫苗。。

Company executives said the updated guidelines have affected uptake. “[Abrysvo vaccinations] are at lower volumes, from a market perspective, than where they were last year,' said Malik, on Tuesday’s call. Malik cited the CDC’s recommendation, as well as the timing of COVID vaccination this year.

公司高管表示，更新后的指导方针影响了吸收。马利克在周二的电话中说：“（Abrysvo疫苗）从市场角度来看，其接种量低于去年。”马利克引用了疾病预防控制中心的建议以及今年新型冠状病毒疫苗接种的时间安排。

CDC advisers, who have since met again following that recommendation, also haven’t endorsed expanding their recommendations to adults younger than 60, or recommending previously vaccinated individuals to get another shot.

此后，CDC顾问再次按照该建议会面，也没有支持将他们的建议扩大到60岁以下的成年人，也没有建议以前接种过疫苗的人再次接种疫苗。

Mikael Dolsten, Pfizer’s departing chief scientific officer, said Tuesday the company is accumulating evidence on revaccination and suggested that an additional dose might be appropriate after several years.

辉瑞公司即将离职的首席科学官米凯尔·多尔斯滕（MikaelDolsten）周二表示，该公司正在积累重新接种疫苗的证据，并建议在几年后增加剂量可能是合适的。

Beyond RSV, Pfizer also talked up its next-generation pneumococcal vaccines that it eventually hopes will replace its top-selling Prevnar 20. One, which covers 25 serotypes of the bacteria that causes disease, is in Phase 2 testing. Another, covering more than 30 serotypes, is in preclinical development..

除了RSV之外，辉瑞还谈到了它的下一代肺炎球菌疫苗，它最终希望它能取代最畅销的Prevnar 20。其中一个涵盖了导致疾病的25种血清型细菌，正在进行第二阶段测试。另一种覆盖30多种血清型的药物正在临床前开发中。。

Both shots would provide additional coverage against pneumococcal disease, but Pfizer has competitors. Merck & Co. recently won approval of a 21-valent shot called Capvaxive, while biotechnology company Vaxcyte impressed with early trial data on a rival product. In a note to clients, analysts at Jefferies said Pfizer’s 25-valent shot might have difficulty competing..

这两种疫苗都将提供针对肺炎球菌疾病的额外保险，但辉瑞有竞争对手。默克公司（Merck&Co.）最近批准了一种名为Capvaxive的21价疫苗，而生物技术公司Vaxcyte对其竞争产品的早期试验数据印象深刻。Jefferies的分析师在给客户的一份报告中表示，辉瑞的25价药水可能难以竞争。。